Plus Therapeutics, Inc. (NASDAQ:PSTV) Stock Has Average Price Target of $51.75 According to Brokerages

Shares of Plus Therapeutics, Inc. (NASDAQ:PSTV) have earned a consensus recommendation of “Hold” from the six brokerages that are presently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating on the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $51.75.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Plus Therapeutics in a report on Friday, July 17th.

Plus Therapeutics Trading Up 11.2%

PSTV opened at $1.88 on Friday. The stock has a fifty day simple moving average of $2.50 and a two-hundred day simple moving average of $4.08. Plus Therapeutics has a 12-month low of $2.90 and a 12-month high of $23.42. The company has a market cap of $12.94 million, a price-to-earnings ratio of -0.82 and a beta of 1.40.

Plus Therapeutics (NASDAQ:PSTV) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($1.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.43). Plus Therapeutics had a negative return on equity of 198.48% and a negative net margin of 230.24%. The firm had revenue of $0.41 million during the quarter, compared to the consensus estimate of $1.11 million. On average, analysts predict that Plus Therapeutics will post -3.76 EPS for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in Plus Therapeutics stock. Citadel Advisors LLC acquired a new position in shares of Plus Therapeutics, Inc. (NASDAQ:PSTV) during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 25,597 shares of the company’s stock, valued at approximately $112,000. Citadel Advisors LLC owned approximately 0.37% of Plus Therapeutics at the end of the most recent reporting period. Institutional investors and hedge funds own 3.28% of the company’s stock.

Plus Therapeutics Company Profile

Plus Therapeutics, Inc is a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for difficult-to-treat cancers. The company’s approach combines radioactive isotopes with nanoparticle-based drug-delivery technology designed to deliver radiation directly to tumors while limiting exposure to surrounding healthy tissue.

Its lead investigational product is rhenium-186 nano liposomes, also known as 186RNL. The treatment is being evaluated for recurrent glioblastoma and leptomeningeal metastases, cancers affecting the brain and spinal cord.